State Street
SMMT icon

State Street’s Summit Therapeutics SMMT Stock Holding History

State Street’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139M Buy
9,536,796
+2,508,636
+36% +$44.5M ﹤0.01% 1291
2026
Q1 		$133M Buy
7,028,160
+391,799
+6% +$6.34M ﹤0.01% 1201
2025
Q4 		$116M Buy
6,636,361
+274,425
+4% +$5.16M ﹤0.01% 1269
2025
Q3 		$131M Buy
6,361,936
+2,344,239
+58% +$56.8M ﹤0.01% 1184
2025
Q2 		$85.5M Sell
4,017,697
-833,691
-17% -$19M ﹤0.01% 1393
2025
Q1 		$93.6M Sell
4,851,388
-751,522
-13% -$15.1M ﹤0.01% 1300
2024
Q4 		$100M Buy
5,602,910
+2,134,396
+62% +$41.4M ﹤0.01% 1329
2024
Q3 		$76M Sell
3,468,514
-654,623
-16% -$9.15M ﹤0.01% 1485
2024
Q2 		$32.2M Sell
4,123,137
-3,991,093
-49% -$21.6M ﹤0.01% 1894
2024
Q1 		$33.6M Buy
8,114,230
+5,658,062
+230% +$22.5M ﹤0.01% 1930
2023
Q4 		$6.41M Buy
2,456,168
+189,599
+8% +$390K ﹤0.01% 2828
2023
Q3 		$4.24M Buy
2,266,569
+12,594
+0.6% +$24K ﹤0.01% 2997
2023
Q2 		$5.66M Buy
2,253,975
+2,131,675
+1,743% +$3.89M ﹤0.01% 2935
2023
Q1 		$214K Buy
122,300
+34,400
+39% +$93.8K ﹤0.01% 4057
2022
Q4 		$374K Buy
+87,900
New +$160K ﹤0.01% 3865
2022
Q2 		– Sell
-313,401
Closed -$768K – 4970
2022
Q1 		$768K Sell
313,401
-23,713
-7% -$59.8K ﹤0.01% 3891
2021
Q4 		$907K Buy
337,114
+916
+0.3% +$4.4K ﹤0.01% 3838
2021
Q3 		$1.68M Buy
336,198
+79,498
+31% +$570K ﹤0.01% 3655
2021
Q2 		$1.92M Buy
+256,700
New +$1.68M ﹤0.01% 3556

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's SMMT Position: Q2 2026 in Review

State Street increased its Summit Therapeutics (SMMT) stake by 36% in Q2 2026, buying an estimated $44.5M and bringing the position to 9,536,796 shares worth $139M. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

State Street first reported a position in SMMT in Q2 2021 and has held it in 19 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • State Street held 9,536,796 shares of Summit Therapeutics worth $139M as of Q2 2026.
  • State Street bought 2,508,636 Summit Therapeutics shares in Q2 2026, an estimated $44.5M.
  • Summit Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1291 holding.
  • State Street first reported a position in Summit Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.